Immunovia (IMMNOV) Q3 2025 earnings summary

Executive summary

• Transitioned from development to commercial stage with the U.S. launch of PancreaSure, a non-invasive blood test for early pancreatic cancer detection, with initial adoption at 10 leading high-risk surveillance centers and strong advocacy from key opinion leaders.

• Launch strategy focused on targeted, low-cost advocacy among key opinion leaders and high-risk centers, with phased commercial investment tied to reimbursement milestones.

• Clinical studies, including AFFIRM and CLARITY, demonstrated high sensitivity and specificity, supporting PancreaSure's value in early detection.

• Received CAP accreditation for the North Carolina laboratory, confirming high operational standards.

Financial highlights

• Q3 2025 net sales were SEK 101,000, primarily from royalty revenue, with PancreaSure test sales expected to impact revenue from Q4 2025.

• Operating loss for Q3 2025 was SEK 25.1 million, down from SEK 31.2 million year-over-year.

• Cash burn reduced to SEK 5.4 million per month, below previous guidance of SEK 8-10 million.

• Ended Q3 with SEK 26.6 million in cash, supported by a 19.0 MSEK bridge loan.

• Rights issue post-quarter raised just under SEK 70 million net, with total gross proceeds of up to SEK 100.2 million, extending cash runway into Q3 2026.

Outlook and guidance

• Commercial investment will increase as reimbursement milestones are achieved, with significant revenue expected in 2026 and beyond.

• Cash position expected to fund operations and clinical studies into Q3 2026.

• Expense and cash burn guidance remains at SEK 8-10 million per month, with R&D costs managed within this range.